Company / Operating Cash Flow
Beam Therapeutics Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$345.1M
FY2025
5-year range
-$347.2M / $22.5M
FY2021-FY2025
Trend
+0.6%
vs FY2024
Sector context
#198 of 216
Health Care
What the data says
Among 216 Health Care companies, Beam Therapeutics Inc. is in the bottom 8% for operating cash flow. Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$345M.
Based on SEC 10-K filings.
-$345M in FY2025.
Declined from -$149M to -$345M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 216This company -$345.1M Sector average $658.7M
▼
-152.4% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 0.6% year-over-year.
- Ranks #198 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$345.1M | +0.6% |
| FY2024 | -$347.2M | -132.7% |
| FY2023 | -$149.2M | -762.3% |
| FY2022 | $22.5M | +134.0% |
| FY2021 | -$66.3M | +8.0% |
| FY2020 | -$72.0M | +0.0% |
| FY2019 | -$72.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026